{
  "query": "NVO",
  "resolved": {
    "ticker": "NVO",
    "cik": "0000353278",
    "title": "NOVO NORDISK A S"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — trial primary completion in ~10 days",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (n/a)",
        "detail": "A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants",
        "nctId": "NCT07532863",
        "date": "2026-07-01"
      },
      "observed": {
        "event": "primary completion in ~10 days",
        "nctId": "NCT07532863"
      },
      "predicted": {
        "event": "SEC 8-K / press release (material trial update)",
        "leadTime": "days–weeks",
        "baseRate": null,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "days–weeks to disclosure",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07532863",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "NOVO NORDISK A S (NVO) — PHASE3 protocol updated 5 days ago",
      "entity": "Novo Nordisk A/S",
      "ticker": "NVO",
      "cik": "0000353278",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight",
        "nctId": "NCT05726227",
        "date": "2025-10-15"
      },
      "observed": {
        "event": "protocol updated 5 days ago",
        "nctId": "NCT05726227"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT05726227",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000353278&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "NOVO NORDISK A S",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": []
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-06-21T09:50:25.029Z"
}